Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 1925Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
Yun Kim,Sangwon Lee,Yohan Kim,In-Jin Jang,SeungHwan Lee
Clinical and Translational Science.2022;15(2)422
[DOI]
2New paradigm for expediting drug development in Asia
Iris Rajman,Masaru Hirano,Wataru Honma,Sylvia Zhao
Drug Discovery Today.2020;25(3)491
[DOI]
3Model-informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets
Alain Munafo,Nadia Terranova,Dandan Li,Ping Liu,Karthik Venkatakrishnan
Clinical and Translational Science.2022;15(2)297
[DOI]
4Pharmacokinetics and tolerability of apremilast in healthy Korean adult men
Ki Young Huh,Yewon Choi,Jim Nissel,Maria Palmisano,Xiaomin Wang,Liangang Liu,Francisco Ramirez-Valle,Howard Lee
Clinical and Translational Science.2021;14(4)1505
[DOI]
5And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC
Sally C.M. Lau,Sai-Hong Ignatius Ou
Journal of Thoracic Oncology.2022;17(10)1144
[DOI]
6Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
Colby S. Shemesh,Phyllis Chan,Hui Shao,Derek-Zhen Xu,Daniel Combs,Shweta Vadhavkar,René Bruno,Benjamin Wu
Liver Cancer.2021;10(5)485
[DOI]
7The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework
Stephen V. Liu,Misako Nagasaka,Victoria Stefaniak,Kristi Gruver,Yong Lin,David Ferry,Mark A. Socinski,Li Zhang
Frontiers in Oncology.2022;12(5)485
[DOI]
8Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
Weimin Wang,Xiang Song,Ying Lou,Liying Du,Dalong Zhu,Zhiguang Zhou
Diabetes, Obesity and Metabolism.2022;24(6)1094
[DOI]
9Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects
Ying Huang,Pryseley Nkouibert Assam,Cong Feng,Rong Su,Paul Dorinsky,Michael Gillen
Pulmonary Pharmacology & Therapeutics.2020;64(6)101976
[DOI]
10In Silieo Study on the Inhibitory Interaction of Drugs with Wild-type CYP2D6.1 and the Natural Variant CYP2D6.17
Koichi Handa,Izumi Nakagome,Noriyuki Yamaotsu,Hiroaki Gouda,Shuichi Hirono
Drug Metabolism and Pharmacokinetics.2014;29(1)52
[DOI]
11Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review
Pi-Lin Sung,Yen-Hou Chang,Kuan-Chong Chao,Chi-Mu Chuang
Gynecologic Oncology.2014;133(2)147
[DOI]
12The necessary conduct: Exploratory multiregional clinical trials in East Asia
Inseung Jeon,Yu Kyong Kim,Ildae Song,Deok Yong Yoon,Ki Young Huh,Xuanyou Jin,Kyung-Sang Yu,SeungHwan Lee,Yuji Kumagai,In-Jin Jang
Clinical and Translational Science.2021;14(6)2399
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal